Oramed, an Israeli pharmaceutical company, said on Thursday a mid-stage trial for its oral insulin capsule met all primary and secondary endpoints.
During the Phase 2a trial, conducted under a U.S. Food and Drug Administration new drug protocol, 30 patients with type 2 diabetes took part in an in-patient setting for one week, Fox News reports.
Endpoints of safety as well as pharmacodynamic and pharmacokinetic effects were evaluated.
Author
Topic
Frontiers: Japanese Cherry Blossom Extract May Slow the Aging of Skin Cells
The Journal of Immunology: High Blood Sugar Enhances Immune Cells’ Ability to Suppress Tumor Growth
A Simple Way to Blunt Blood Sugar Spikes After Meals
JES: Longer Sleep May Increase the Risk of Kidney Damage in People with Diabetes
AJCN: Regular Peanut Consumption May Reduce the Risk of Type 2 Diabetes
Metabolism: A Consistent Daily Routine Improves Blood Sugar Control in Diabetes
make preferable